Market Overview

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy

Share:

Promising new platform can rapidly respond to emerging infectious
diseases

SAB
Biotherapeutics, Inc. (SAB)
, a clinical-stage biopharmaceutical
company, today announced that its anti-Ebola immunotherapy (SAB-139)
provided "100% protection against a lethal dose of the Ebola virus" in a
recent animal study published in The
Journal of Infectious Diseases
. The study was conducted
by the National
Interagency Confederation for Biological Research
and other
collaborators including United
States Army Medical Research Institute of Infectious Diseases (USAMRIID)

and the Naval
Medical Research Center (NMRC)
.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180815005602/en/

New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to ...

New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics)

According to the World Health Organization, Ebola virus disease (EVD),
formerly known as Ebola hemorrhagic fever, is a severe, often fatal
illness in humans with an average fatality rate around 50%. Case
fatality rates have varied from 25% to 90% in past outbreaks, and there
is currently no licensed treatment proven to neutralize the virus.

During recent outbreaks of EVD in West Africa, passive immunotherapy
with convalescent plasma containing polyclonal antibodies from recovered
patients was used as an effective treatment. However, the amount and
availability of these medicines are limited by the number of survivors.

SAB-139 was produced from SAB's proprietary DiversitAb™ platform
utilizing transgenic cattle (Tc Bovine™) to produce large amounts of
natural human, rather than bovine, antibodies in response to an
antigen—in this case EVD.

"This study demonstrates that a human polyclonal antibody-based product
can be used to prevent EVD in the most advanced animal model available.
This is impressive when one considers that SAB-139 did not require the
use of plasma or cells from human EVD survivors," said Jay Hooper, M.D.,
chief of the molecular virology branch of USAMRIID. "The ability to
rapidly produce a human polyclonal antibody product without the need for
material from infected animals or humans could be particularly useful
when combating novel emerging infectious diseases."

In the study, all animals treated with SAB-139 at one-day or three-days
post-infection survived versus none of the control animals. In addition,
the animals treated with SAB-139 exhibited no symptoms of EVD.

"Polyclonal antibodies are a powerful tool against emerging infectious
diseases," said Eddie J. Sullivan, PhD, SAB Biotherapeutics president
and CEO. "They are our body's natural defense to combat pathogens. With
our platform, we can rapidly produce large amounts of targeted human
antibodies without using humans—the limiting factor in current
convalescent therapies in responding to a widespread outbreak."

To produce the immunotherapy, Tc Bovine were vaccinated with the EVD
antigen. Within a brief period of time, they produced significant
amounts of fully human antibodies to combat the virus. Plasma was then
collected, in the same way it is collected from human donors, and
purified to isolate the antibodies that become the treatment.

"Our DiversitAb platform continues to demonstrate the ability to rapidly
produce targeted immunotherapies to emerging infectious diseases with
epidemic potential," added Sullivan. "We will continue to work with our
collaborators to develop life-saving medicines for both patients and
those who care for them to prevent or stop an outbreak."

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB) is a clinical stage biopharmaceutical
company leading the science and manufacturing of human antibody
therapeutics. Utilizing some of the most advanced polyclonal antibody
science, SAB is delivering the world's first large-scale platform to
create fully human immunoglobulins. This natural production platform
holds the potential for treatment of public health problems, rare
conditions, long-term diseases and global pandemic threats.

View Comments and Join the Discussion!